) vaccines division, Sanofi Pasteur, announced that The Lancet has
published data from a phase III study on the company's dengue
The randomized, observer-blind, placebo-controlled, multi-center
phase III study enrolled 10,275 children aged between 2 and 14
years in Asia. The study compared the use of three injections of
the dengue vaccine and placebo at intervals of six months.
Data from the study revealed that the use of the dengue vaccine
resulted in an 88.5% reduction of dengue hemorrhagic fever (the
severe form of dengue). Additionally, a clinically important
reduction in the risk of hospitalization due to dengue (67%) and
overall efficacy against symptomatic dengue (56.5%) was also
According to the World Health Organization (WHO), approximately 100
million people suffer from dengue infection each year. Record
breaking epidemics in several countries including Brazil and
Singapore were observed in 2013. The WHO has targeted to reduce
morbidity and mortality by 25% and 50% by 2020, respectively.
However, there is no specific treatment currently available for
this disease, indicating an unmet market need. Sanofi aims to tap
this market with its dengue vaccine candidate. Another pivotal
phase III study on the dengue vaccine is ongoing in Latin America.
We note that Sanofi possesses one of the world's leading vaccine
operations with total sales of €3.7 billion in 2013. The company's
portfolio includes pediatric vaccines, influenza vaccines, adult
and adolescent booster vaccines, meningitis vaccines, and travel
and endemic vaccines. Sanofi also has a strong position in both
seasonal and pre-pandemic influenza vaccines. Sanofi continues to
expand its vaccine business. We expect a significant ramp in
vaccine sales over the next several years.
Sanofi carries a Zacks Rank #3 (Hold). Some better-ranked stocks in
the health care sector include
Johnson & Johnson
). All these stocks hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
SANOFI-AVENTIS (SNY): Free Stock Analysis
ASTRAZENECA PLC (AZN): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
ABBVIE INC (ABBV): Free Stock Analysis Report
To read this article on Zacks.com click here.